We have decided to expand on these observations and include glucagon-like peptide-1 (GLP-1) given that GLP-1 receptor agonists can reduce cancer incidence, particularly in patients with type-2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.